Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01147003 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures
A Phase 2 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT01147003 is a Phase 2 study that has completed, run by Novartis. The registered enrollment target is 93 participants.
The verdict
NCT01147003, a Phase 2 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
This study will assess the efficacy and safety of BGG492 as adjunctive treatment in patients with partial onset seizures.
Interventions
- DRUG Placebo
- DRUG Investigational new drug, company code: BGG492
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01147003
The ClinicalTrials.gov registry entry for NCT01147003 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01147003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01147003 about?
NCT01147003 is a clinical study titled "Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures". This study will assess the efficacy and safety of BGG492 as adjunctive treatment in patients with partial onset seizures.
What is the current status of trial NCT01147003?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2010-06. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01147003?
The interventions under investigation include: Placebo (DRUG), Investigational new drug, company code: BGG492 (DRUG).
Who is sponsoring clinical trial NCT01147003?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.